Do analysts rate BFRG or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BFRG or VIVS more profitable?

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. Bullfrog AI's return on equity of -150.36% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -150.36% -127.98% VivoSim Labs -11,016.07% -612.23% -177.02%

Does the media refer more to BFRG or VIVS?

In the previous week, VivoSim Labs had 3 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for VivoSim Labs and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.71 beat VivoSim Labs' score of 0.23 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive VivoSim Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ISPC or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ISPC or VIVS?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.72 -$10.49M -$56.44 N/A VivoSim Labs $130K 31.69 -$13.84M -$4.47 N/A

Is ISPC or VIVS more profitable?

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% VivoSim Labs -11,016.07% -612.23% -177.02%

Do analysts rate VIVS or TBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VIVS or TBIO more profitable?

Telesis Bio has a net margin of -336.59% compared to VivoSim Labs' net margin of -11,016.07%. Telesis Bio's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -11,016.07% -612.23% -177.02% Telesis Bio -336.59% N/A -61.89%

Do analysts rate BFRGW or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BFRGW or VIVS?

Bullfrog AI has higher revenue and earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $298.80K N/A N/A N/A N/A VivoSim Labs $130K 31.69 -$13.84M -$4.47 N/A

Is BFRGW or VIVS more profitable?

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. Bullfrog AI's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A N/A N/A VivoSim Labs -11,016.07% -612.23% -177.02%

Do analysts prefer OABIW or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, OABIW or VIVS?

OmniAb has higher revenue and earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A VivoSim Labs $130K 31.69 -$13.84M -$4.47 N/A

Is OABIW or VIVS more profitable?

OmniAb has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. OmniAb's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets OmniAb N/A N/A N/A VivoSim Labs -11,016.07% -612.23% -177.02%

VivoSim Labs (VIVS) Competitors

$0.25 +0.02 (+9.38%)

Closing price 09/21/2026 04:00 PM Eastern

Extended Trading

$0.26 +0.01 (+3.91%)

As of 08:23 AM Eastern

Compare

VIVS vs. BFRG, ISPC, TBIO, BFRGW, and OABIW

Should you buy VivoSim Labs stock or one of its competitors? VivoSim Labs's main competitors and comparable companies include Bullfrog AI (BFRG), iSpecimen (ISPC), Telesis Bio (TBIO), Bullfrog AI (BFRGW), and OmniAb (OABIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does VivoSim Labs compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Bullfrog AI has a beta of -2.71, suggesting that its share price is 371% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 1.0% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, VivoSim Labs had 3 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for VivoSim Labs and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.71 beat VivoSim Labs' score of 0.23 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
VivoSim Labs	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. Bullfrog AI's return on equity of -150.36% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

Bullfrog AI has higher earnings, but lower revenue than VivoSim Labs. Bullfrog AI is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	76.17	-$6.50M	-$0.46	N/A
VivoSim Labs	$130K	31.69	-$13.84M	-$4.47	N/A

Summary

Bullfrog AI beats VivoSim Labs on 9 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to iSpecimen?

iSpecimen (NASDAQ:ISPC) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, VivoSim Labs had 4 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for iSpecimen. VivoSim Labs' average media sentiment score of 0.23 beat iSpecimen's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
iSpecimen	Neutral
VivoSim Labs	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

iSpecimen has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.72	-$10.49M	-$56.44	N/A
VivoSim Labs	$130K	31.69	-$13.84M	-$4.47	N/A

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by insiders. Comparatively, 1.0% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

iSpecimen beats VivoSim Labs on 9 of the 13 factors compared between the two stocks.

How does VivoSim Labs compare to Telesis Bio?

VivoSim Labs (NASDAQ:VIVS) and Telesis Bio (NASDAQ:TBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Telesis Bio has a net margin of -336.59% compared to VivoSim Labs' net margin of -11,016.07%. Telesis Bio's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
Telesis Bio	-336.59%	N/A	-61.89%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

VivoSim Labs has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market.

VivoSim Labs has higher earnings, but lower revenue than Telesis Bio. VivoSim Labs is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	31.69	-$13.84M	-$4.47	N/A
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

In the previous week, VivoSim Labs had 4 more articles in the media than Telesis Bio. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for Telesis Bio. VivoSim Labs' average media sentiment score of 0.23 beat Telesis Bio's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
Telesis Bio	Neutral

8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Telesis Bio beats VivoSim Labs on 8 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRGW) and VivoSim Labs (NASDAQ:VIVS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Bullfrog AI has higher revenue and earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	N/A	N/A	N/A	N/A
VivoSim Labs	$130K	31.69	-$13.84M	-$4.47	N/A

In the previous week, VivoSim Labs had 4 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for Bullfrog AI. VivoSim Labs' average media sentiment score of 0.23 beat Bullfrog AI's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Bullfrog AI	Neutral
VivoSim Labs	Neutral

8.2% of VivoSim Labs shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. Bullfrog AI's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

Summary

VivoSim Labs beats Bullfrog AI on 5 of the 9 factors compared between the two stocks.

How does VivoSim Labs compare to OmniAb?

OmniAb (NASDAQ:OABIW) and VivoSim Labs (NASDAQ:VIVS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

OmniAb has a net margin of 0.00% compared to VivoSim Labs' net margin of -11,016.07%. OmniAb's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

8.2% of VivoSim Labs shares are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, VivoSim Labs had 4 more articles in the media than OmniAb. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for OmniAb. VivoSim Labs' average media sentiment score of 0.23 beat OmniAb's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
VivoSim Labs	Neutral

OmniAb has higher revenue and earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
VivoSim Labs	$130K	31.69	-$13.84M	-$4.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

VivoSim Labs beats OmniAb on 5 of the 9 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.77M	$10.40B	$7.25B	$12.97B
Dividend Yield	N/A	1.46%	2.53%	12.80%
P/E Ratio	-0.06	73.85	275.10	25.77
Price / Sales	31.69	107.16	692.96	115.26
Price / Cash	N/A	27.47	28.04	34.72
Price / Book	-0.59	5.70	10.49	6.36
Net Income	-$13.84M	$56.67B	$3.49B	$358.17M
7 Day Performance	-8.88%	3.74%	0.77%	1.58%
1 Month Performance	-13.18%	0.41%	-2.84%	-2.98%
1 Year Performance	-93.33%	28.09%	16.64%	5.63%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	0.7857 of 5 stars	$0.25 +9.4%	N/A	-94.0%	$3.77M	$130K	N/A	11	News Coverage
BFRG Bullfrog AI	1.1975 of 5 stars	$0.47 +9.2%	N/A	-62.7%	$7.95M	$120K	N/A	4	Positive News
ISPC iSpecimen	0.2839 of 5 stars	$1.35 -1.5%	N/A	-97.7%	$3.45M	$1.93M	N/A	60	Positive News
TBIO Telesis Bio	N/A	$0.00 flat	N/A	+0.0%	$2K	$225.09M	N/A	200
BFRGW Bullfrog AI	N/A	$0.09 +3.1%	N/A	-84.3%	$0.00	$298.80K	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. BFRG, ISPC, TBIO, BFRGW, and OABIW

How does VivoSim Labs compare to Bullfrog AI?

Summary

How does VivoSim Labs compare to iSpecimen?

Summary

How does VivoSim Labs compare to Telesis Bio?

Summary

How does VivoSim Labs compare to Bullfrog AI?

Summary

How does VivoSim Labs compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. BFRG, ISPC, TBIO, BFRGW, and OABIW

How does VivoSim Labs compare to Bullfrog AI?

Which has more risk and volatility, BFRG or VIVS?

Do institutionals & insiders believe in BFRG or VIVS?

Does the media refer more to BFRG or VIVS?

Do analysts rate BFRG or VIVS?

Is BFRG or VIVS more profitable?

Which has higher earnings & valuation, BFRG or VIVS?

Summary

How does VivoSim Labs compare to iSpecimen?

Does the media refer more to ISPC or VIVS?

Do analysts rate ISPC or VIVS?

Is ISPC or VIVS more profitable?

Which has more volatility and risk, ISPC or VIVS?

Which has preferable valuation & earnings, ISPC or VIVS?

Do institutionals and insiders believe in ISPC or VIVS?

Summary

How does VivoSim Labs compare to Telesis Bio?

Is VIVS or TBIO more profitable?

Do analysts rate VIVS or TBIO?

Which has more volatility & risk, VIVS or TBIO?

Which has stronger earnings and valuation, VIVS or TBIO?

Does the media prefer VIVS or TBIO?

Do institutionals & insiders believe in VIVS or TBIO?

Summary

How does VivoSim Labs compare to Bullfrog AI?

Which has preferable valuation and earnings, BFRGW or VIVS?

Does the media refer more to BFRGW or VIVS?

Do insiders & institutionals believe in BFRGW or VIVS?

Do analysts rate BFRGW or VIVS?

Is BFRGW or VIVS more profitable?

Summary

How does VivoSim Labs compare to OmniAb?

Is OABIW or VIVS more profitable?

Do insiders and institutionals believe in OABIW or VIVS?

Does the media refer more to OABIW or VIVS?

Which has better earnings and valuation, OABIW or VIVS?

Do analysts prefer OABIW or VIVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools